Bayer wants to protect its patent on the anthrax-fighting antibiotic, but that doesn't necessarily mean it couldn't grant an emergency exemption to a generic drug maker.
Investigators have turned up no physical evidence linking Hatfill to the anthrax attacks, according to federal sources, and say they don't consider him a suspect in the case.